|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||42.28 - 42.45|
|52 Week Range||31.81 - 42.45|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||27.63|
|Forward Dividend & Yield||1.07 (2.53%)|
|Ex-Dividend Date||Mar 05, 2019|
|1y Target Est||42.65|
A new survey is shedding light on how businesses view the economy and the future of e-commerce. According to Alibaba.com, 62% of small and medium B2B companies are feeling upbeat about the U.S. economy. Head of Alibaba.com, North America John Caplan breaks down the survey's findings. Yahoo Finance's Zack Guzman, Heidi Chung & Julia La Roche join in on the conversation.
Jan.14 -- Bill Anderson, head of the pharmaceuticals division at Roche Holding AG, discusses the company’s recent acquisitions, its focus on innovation in drug development, and reforms needed to reduce drug costs for patients. He speaks with Bloomberg’s Taylor Riggs on the sidelines of the JPMorgan Healthcare Conference on "Bloomberg Markets." (Corrects guest's title in headline)
Cyxtera Federal Group CISO and Executive Vice President Leo Taddeo joins the On The Move panel to discuss how Iranian cyberattacks could impact the United States.
At a news conference on Wednesday, former Nissan CEO turned fugitive Carlos Ghosn made his first public appearance since fleeing Japan, where the disgraced auto executive explained the reasons behind his now infamous escape.
Bill Ackman publicly-traded hedge fund firm, Pershing Square Capital, ended the year up 58.1% in 2019. Yahoo Finance's Julia La Roche joins On the Move to discuss.
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...
Mega-caps, usually the largest and most established companies in the stock market, tend to be stable, and many of them pay dividends based on their earnings.
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
Partnership to leverage Illumina’s extensive decentralised installed base with Roche’s expertise in assay development and to provide broad access to clinical oncology.
Drug company Hoffmann-La Roche (OTCMKTS: RHHBY) bilked U.S. federal and state governments out of $1.5 billion by misrepresenting clinical studies and falsely claiming that its well-known influenza medicine Tamiflu was effective at containing potential pandemics, according to a recently unsealed whistleblower lawsuit.
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study.
Alexis Borisy’s start-up plans to make fast followers—unique medications, protected by their own patents, that copy a drug or class of drugs
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).
Biotech stocks are now the top-ranked industry group based on price performance thanks to new technology and deals. Look for new cancer drugs and genetic medicines in 2020.
Mutual fund managers with a remit to invest in stocks across the globe are underweight one of the hottest stocks around.
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.
Bank of America expects European stocks broadly to rise this year, but its key underweight call is the pharmaceutical sector, and the recommendation has nothing to do with talk of reining in U.S. drug prices.
J.P. Morgan’s Richard Vosser upgraded (SAN)(ticker: SAN.France) to Overweight from Neutral, and named (ROG)(ROG.Switzerland), (NOVO-B)(NOVOB.Copenhagen), and (AZN)(AZN) as top picks. As for Galapagos, Vosser downgraded the stock to Neutral after its blockbuster 2019.
European stocks on Monday slumped in a broad-based decline that was the worst in more than a month on worries about ratcheting Middle East tensions.